Tessa Therapeutics

14/12/2022

Thank you to the American Society of Hematology for hosting us at . This was a very exciting conference for Tessa Therapeutics highlighted by two oral podium presentations featuring our allogeneic and autologous CAR-T platforms. Data presented from our TT11X program not only demonstrated the technology to be a potentially safe and efficacious treatment for CD30-positive lymphomas, but also highlighted a potential to extend the EBVST platform to other cancer indications, including solid tumors where there is significant unmet medical need. We are proud to be leading these advancements and look forward to an exciting 2023. See tessacell.com for our press releases and more information

13/12/2022

Ivan Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics discusses our autologous data presented at : “We continue to be intrigued by the data being generated from our ongoing Phase 2 trial of TT11, which show the therapy to be safe and well tolerated, along with clear signals of efficacy, in patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma.”

13/12/2022

Tessa Therapeutics' autologous CD30 therapy trial at the The University of Texas MD Anderson Cancer Center demonstrated a complete response rate of 60% and an overall response rate of 73.3% in 15 heavily pre-treated r/r cHL patients, suggesting strong anti-tumor responses. Further, data highlighted in an oral podium presentation has identified circulating tumor DNA (ctDNA) analysis as a potential measure of response in cHL after CD30 targeted CAR T-cell therapy.
Read more here: https://www.tessacell.com/2022/12/13/tessa-therapeutics-announces-updated-safety-efficacy-and-biomarker-data-from-phase-2-trial-of-autologous-cd30-car-t-therapy-tt11-in-relapsed-or-refractory-classical-hodgkin-lymphoma/

12/12/2022

Ivan Horak, M.D., Chief Medical Officer and Chief Scientific Officer of Tessa Therapeutics discusses our off-the-shelf CART-T Cell therapy clinical data presented at on Saturday: “The safety and efficacy data presented at ASH were very compelling and indicate that our “off-the-shelf” CD30.CAR EBVST cell therapy platform could provide a potential leap forward in the treatment of CD30 positive lymphomas.”

10/12/2022

Our off-the-shelf therapy demonstrated a 79% overall response rate and complete disappearance of tumor in six patients with advanced CD30-positive Hodgkin lymphoma. The strongest responses were achieved in patients treated at the higher dose levels with additional infusions resulting in increasing effectiveness. TT11X was well tolerated with no dose limiting toxicities observed, including no evidence of graft-versus-host disease (GVHD). These results suggest CD30.CAR EBVSTs offer a promising platform for off-the-shelf cancer immunotherapy.
https://www.globenewswire.com/news-release/2022/12/10/2571406/0/en/Tessa-Therapeutics-Announces-New-Clinical-Data-from-Phase-1-Allogeneic-Study-Presented-at-2022-Annual-Meeting-of-American-Society-of-Hematology-ASH.html

Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive...

09/12/2022

The 64th American Society of Hematologyogy conference is this weekend Dec 10-13. We are presenting two oral podium presentations and a poster on clinical data from Tessa’s allogenic and autologous CAR-T cell therapy clinical studies.

The first oral podium presentation is on Dec. 10 at 1pm CT and highlights our CD30 CAR-EBVST off-the-shelf therapy . The second oral podium presentation is on Dec. 12 at 5:45pm CT and features data from our CD30 CAR-T autologous program . Additionally, data from the Phase 2 trial of TT11 will be featured in a poster presentation on Dec. 11.



Read more at https://www.tessacell.com/2022/11/03/tessa-therapeutics-announces-three-abstracts-highlighting-data-from-autologous-and-allogeneic-cell-therapy-programs-accepted-for-presentation-at-64th-ash-annual-meeting-and-exposition/

15/09/2022

Thank you Asia-Pacific Cell & Gene Therapy Excellence Awards 2022 for recognizing Tessa under the “Most Promising Off-the-Shelf Therapies” category. We had a great time at the ceremony!

14/09/2022

Tessa Therapeutics' allogeneic “off-the-shelf” CD30.CAR EBVST cell therapy TT11X has been recognized in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards 2022

TT11X has been developed following research on the unique properties of virus specific T-cells (VSTs). These highly specialized T cells have the ability to recognize and kill infected cells while activating other parts of the immune system for a coordinated response. Allogeneic VSTs without any form of genetic modification have demonstrated a strong safety profile and efficacy in early trials with minimal risk of graft rejection and Graft vs Host Disease (GVHD).

Read more about ACGTEA and TT11X here: https://www.tessacell.com/2022/09/14/tessa-therapeutics-recognized-in-most-promising-off-the-shelf-therapies-category-at-asia-pacific-cell-gene-therapy-excellence-awards-2022/

Tessa Therapeutics today announced that TT11X, the company’s allogeneic “off-the-shelf” CD30.CAR EBVST cell therapy, has been recognized in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022.

02/09/2022

Tessa Therapeutics features in The Business Times! Sharanya Pillai does a deep dive with Thomas Willemsen on our pipeline and future plans. Read the full story here: https://www.businesstimes.com.sg/garage/tessa-therapeutics-new-ceo-bullish-on-moonshot-in-off-the-shelf-cancer-therapy

SINGAPORE biotech firm Tessa Therapeutics is out to present a renewed image to investors as it works towards commercialising new cell therapies for lymphoma, including an off-the-shelf option that no player has brought to market yet. Read more at The Business Times.

22/08/2022

Tessa Therapeutics CEO Thomas Willemsen features in FierceBiotech. Read the article by Gabrielle Masson here: https://www.fiercebiotech.com/biotech/ex-takeda-leader-takes-reins-tessas-ceo-after-126m-series

After numerous C-suite shake-ups, Tessa Therapeutics is hoping to find some steady footing with former Takeda exec Thomas Willemsen, who will take the reins as CEO to usher the CAR-T biotech throug | Former Takeda exec Thomas Willemsen will be taking the reins as Tessa Therapeutic’s new president ...

22/08/2022

The Business Times' Sharanya Pillai reports on Tessa Therapeutics new CEO Thomas Willemsen.
Read the full story here: https://www.businesstimes.com.sg/garage/tessa-therapeutics-appoints-ex-takeda-executive-as-ceo

SINGAPORE biotech Tessa Therapeutics on Monday (Aug 22) named a new CEO and president, Thomas Willemsen, a former Asia-Pacific senior vice president at Japan’s Takeda Pharmaceutical Company. Read more at The Business Times.

22/08/2022

22/08/2022

We are pleased to announce the appointment of Thomas Willemsen as our President and Chief Executive Officer effective October 1, 2022. Mr. Willemsen brings more than 25 years of international management and leadership experience in the pharmaceutical industry to Tessa. Read more about his bio here:

https://www.tessacell.com/2022/08/22/tessa-therapeutics-appoints-thomas-willemsen-as-president-and-ceo/

17/08/2022

Tessa Therapeutics Phase 1b TT11 ACTION trial features in Precision Oncology News!
TT11, our autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy, will be investigated in combination with Bristol Myers Squibb's nivolumab as a potential second-line treatment for patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL). Read the article at https://www.precisiononcologynews.com/cancer/tessa-therapeutics-starts-trial-car-t-cell-therapy-bmss-opdivo-classical-hodgkin-lymphoma?_ga=2.148068407.1633573820.1660759594-1821758190.1660759594&adobe_mc=MCMID%3D07540098108617061241679616989317269520%7CMCORGID%3D138FFF2554E6E7220A4C98C6%2540AdobeOrg%7CTS%3D1660759709&CSAuthResp=1%3A%3A2474492%3A273%3A24%3Asuccess%3A8A1D1DAB0679602FA81BE7663CA879B7 #.Yv0u6C7MLrc

The firm is evaluating the combination in the ACTION trial involving 14 relapsed or refractory CD30-positive classical Hodgkin lymphoma patients after chemo.

17/08/2022

https://www.tessacell.com/2022/08/17/tessa-therapeutics-doses-first-patient-in-phase-1b-clinical-trial-investigating-tt11-in-combination-with-nivolumab-for-the-treatment-of-relapsed-refractory-classical-hodgkin-lymphoma-chl/

17/08/2022

Tessa Therapeutics has announced the dosing of the first patient in a Phase 1b clinical trial investigating TT11, the company’s autologous CD30 chimeric antigen receptor T- cell (CAR-T) therapy, in combination with Bristol Myers Squibb’s nivolumab as a potential second-line treatment for patients with relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL).

Read the full release here: https://www.tessacell.com/2022/08/17/tessa-therapeutics-doses-first-patient-in-phase-1b-clinical-trial-investigating-tt11-in-combination-with-nivolumab-for-the-treatment-of-relapsed-refractory-classical-hodgkin-lymphoma-chl/

Tessa Therapeutics today announced the dosing of the first patient in a Phase 1b clinical trial investigating TT11, the company’s autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy, in combination with Bristol Myers Squib’s nivolumab as a potential second-line treatment for patient...

05/07/2022

Tessa Therapeutics features in this CapitaLand feature highlighting the sustainable industrial development supporting our cancer therapies. Read more here:

How one start-up is bringing triumph to cancer patients.

13/06/2022

Tessa Therapeutics to host scientific session on CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference on June 23, 2022.

The conference is organized by the SingHealth Duke-NUS Cell Therapy Centre (SDCT) and Regenerative Medicine Institute of Singapore (REMEDIS), and will run for 2 days.


Read more about the presentation here:

Tessa Therapeutics today announced that the company will host a scientific session during the SDCT-REMEDIS Cell Therapy Conference 2022 being held virtually from June 23-24, 2022.